Gencinia (Cinnamomum burmannii)

Cinnamomum burmannii (Gencinia or Padang cassia) is a cinnamon species rich in cinnamaldehyde and phenolic compounds that exert antioxidant and anti-inflammatory effects. Its primary mechanisms involve free radical scavenging and inhibition of the lipoxygenase enzyme pathway involved in inflammatory signaling.

Origin & History

Gencinia (Cinnamomum burmannii) is Indonesian cinnamon or cassia, a tropical evergreen tree native to Southeast Asia, particularly Indonesia and Vietnam. The primary source material is the inner bark, processed through extraction methods including methanol extraction, ethyl acetate fractionation, and steam distillation to yield essential oils containing 68-90% cinnamaldehyde.

Historical & Cultural Context

Cinnamomum burmannii has been used in Indonesian traditional medicine for its pharmaceutical and biological activities. The bark and leaves have been historically assessed for pectic substances and essential oils, though specific duration of use or traditional medicine systems are not quantified in available research.

Health Benefits

• Antioxidant activity: Contains phenolic compounds (82.42-316.26 mg GAE/g) and cinnamaldehyde with free radical scavenging properties demonstrated in DPPH assays (in vitro evidence only)
• Anti-inflammatory potential: Ethyl acetate fraction shows soybean lipoxygenase (SLO) inhibition with IC50=60 μM for 2-hydroxy-cinnamaldehyde (in vitro evidence only)
• Rich in bioactive compounds: Contains catechin, epicatechin, protocatechuic acid, and procyanidin B2 (phytochemical analysis only)
• Essential oil yield: Bark produces 3.2±0.07 wt% essential oil with antimicrobial compounds like borneol and eucalyptol (composition data only)
• Traditional medicine use: Historically used in Indonesian traditional medicine for pharmaceutical and biological activities (traditional use evidence only)

How It Works

Cinnamaldehyde and phenolic compounds in Cinnamomum burmannii neutralize free radicals by donating hydrogen atoms, as demonstrated in DPPH radical scavenging assays. The ethyl acetate fraction inhibits soybean lipoxygenase (SLO) with an IC50 of approximately 60 μg/mL, disrupting the arachidonic acid cascade that produces pro-inflammatory leukotrienes. These dual mechanisms suggest both direct antioxidant protection and indirect suppression of lipid peroxidation-driven inflammation.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses for Cinnamomum burmannii were identified in the research. Available data is limited to phytochemical profiles, in vitro antioxidant activity assessments, and biological assays like soybean lipoxygenase inhibition studies.

Clinical Summary

Current evidence for Cinnamomum burmannii is based primarily on in vitro studies measuring phenolic content (82.42–316.26 mg GAE/g) and enzyme inhibition assays rather than human clinical trials. DPPH assays confirm meaningful free radical scavenging capacity, and SLO inhibition data suggests anti-inflammatory potential, but neither endpoint has been validated in randomized controlled trials or animal dose-response models specific to this species. The extrapolation of these findings to human health outcomes requires significant caution, as bioavailability, effective human dosages, and clinical endpoints remain unstudied. Overall, the evidence base is preliminary and mechanistic, not yet sufficient to support therapeutic claims.

Nutritional Profile

Gencinia (Cinnamomum burmannii), also known as Indonesian cassia or Padang cinnamon, is used primarily as a spice and traditional remedy rather than a macronutrient source. Per typical serving (1-6 g ground bark): Calories: ~6-36 kcal; Carbohydrates: ~4.8-29 g (predominantly dietary fiber ~3.2-19 g, representing ~53% of dry weight); Protein: ~0.24-1.44 g; Fat: ~0.07-0.42 g. **Key Bioactive Compounds:** • Cinnamaldehyde: Primary volatile compound, typically 60-90% of essential oil fraction (essential oil yield ~1-4% of dry bark weight), responsible for characteristic aroma and most biological activities. • Trans-cinnamic acid and o-methoxycinnamaldehyde: Present in smaller quantities as related phenylpropanoids. • 2-Hydroxycinnamaldehyde: Notable bioactive with demonstrated lipoxygenase inhibition (IC50 = 60 μM against soybean lipoxygenase). • Coumarin: Notably HIGH in C. burmannii compared to other Cinnamomum species, reported at ~2,100-4,400 mg/kg (significantly exceeding the EU tolerable daily intake of 0.1 mg/kg body weight at higher consumption levels; a major safety concern distinguishing this species from C. verum/true cinnamon which contains only trace amounts ~0.004 mg/kg). • Total phenolic content: 82.42-316.26 mg gallic acid equivalents (GAE)/g extract, varying significantly by extraction solvent and fraction (ethyl acetate fractions tend toward higher values). • Catechins and proanthocyanidins (condensed tannins): Present as oligomeric polyphenols contributing to antioxidant capacity. • Eugenol: Minor volatile component (~1-5% of essential oil). • Minerals (per 100 g ground bark, approximate): Calcium ~1,002 mg; Iron ~8.3 mg; Manganese ~17.5 mg (exceptionally high, ~760% DV per 100 g); Magnesium ~60 mg; Potassium ~431 mg; Zinc ~1.8 mg; Phosphorus ~64 mg. • Vitamins: Small amounts of vitamin A (~15 μg RAE/100 g), vitamin K (~31 μg/100 g), and trace B-vitamins (niacin, riboflavin). **Bioavailability Notes:** Cinnamaldehyde is rapidly absorbed and metabolized to cinnamic acid and hippuric acid; oral bioavailability is moderate but affected by first-pass metabolism. Polyphenolic compounds (catechins, proanthocyanidins) have generally low oral bioavailability (estimated 5-15%) due to poor intestinal absorption and extensive hepatic conjugation. Coumarin is readily absorbed orally with high bioavailability (~60-100%), which amplifies hepatotoxicity risk at repeated doses. Water-based extraction (teas, decoctions) preferentially extracts polyphenols and water-soluble compounds while reducing coumarin and essential oil extraction compared to alcohol-based or lipophilic preparations. Mineral bioavailability may be reduced by tannin and fiber content that chelate divalent cations.

Preparation & Dosage

No clinically studied dosage ranges are available for Cinnamomum burmannii as human trials are absent. Studies only describe essential oil yields and extract compositions without therapeutic dosing specifications. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ceylon cinnamon, chromium picolinate, alpha-lipoic acid, bitter melon extract, gymnema sylvestre

Safety & Interactions

Cinnamomum burmannii contains relatively high levels of coumarin compared to Ceylon cinnamon (Cinnamomum verum), and chronic high-dose consumption may pose hepatotoxic risk, particularly in individuals with pre-existing liver conditions. It may potentiate the effects of anticoagulant medications such as warfarin due to coumarin content, and caution is warranted when combined with antidiabetic drugs given cinnamon's reported blood glucose-lowering properties. Pregnant and breastfeeding women should avoid supplemental doses beyond culinary amounts due to insufficient safety data. Individuals with cinnamon or Lauraceae family allergies should avoid this ingredient entirely.